, Volume 53, Issue 5, pp 1001-1003

Insulin glargine and insulin have identical effects on proliferation and phosphatidylinositol 3-kinase/AKT signalling in rat thyrocytes and human follicular thyroid cancer cells

This is an excerpt from the content

To the Editor: The mitogenic potency of the analogous insulin glargine (A21Gly,B31Arg,B32Arg human insulin) is currently under heated debate [1], since several clinical studies have raised the possibility of insulin glargine treatment having a carcinogenic potential, especially in breast cancer [2]. Moreover, latest data from Shukla et al. [3] suggest that insulin glargine may indeed trigger cellular proliferation in MCF-7 breast cancer cells at lower dosages than normal insulin.

In the past years, the insulin/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signalling cascade has emerged as a central mediator of thyroid carcinogenesis [4]. Our group recently observed that PI3K/AKT mediated inactivation of the tumour suppressor forkhead box O (FOXO) 3 is a hallmark of follicular and papillary thyroid carcinogenesis [5]. Physiologically, FOXO3 accumulates in the nucleus, where it controls the transcription of anti-proliferative and pro-apoptotic targets such as growth arrest a

K. Müller and C. Weidinger contributed equally to this study.